Rationale for combinatory chronic lymphocytic leukaemia treatment paradigms in the era of the B-cell receptor pathway and anti-apoptotic inhibitors: how do we mix, match, and move forward?
- PMID: 27984636
- DOI: 10.1111/bjh.14446
Rationale for combinatory chronic lymphocytic leukaemia treatment paradigms in the era of the B-cell receptor pathway and anti-apoptotic inhibitors: how do we mix, match, and move forward?
Keywords: B-cell receptor pathway inhibitors; anti-apoptotic inhibitors; chronic lymphocytic leukaemia treatment paradigms.
Comment on
-
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.Br J Haematol. 2017 Feb;176(3):412-420. doi: 10.1111/bjh.14447. Epub 2016 Dec 16. Br J Haematol. 2017. PMID: 27982425 Free PMC article. Clinical Trial.